\-\ Texto\\:\\ \ \(0\)\
\-\ pe\\ \\â\\€\\“\\ noncontributory\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ labs\\ \\â\\€\\“\\ pt\\ 14\\.1\\ \\ ptt\\ 34\\.5\\ \\ inr\\ 1\\.1\\ \\ cbc\\ 6\\.6\\/15\\.2\\/44\\/180\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ a\\-1\\-fetoprotein\\ 1\\.9\\ \\ ast\\/alt\\ 37\\/33\\ \\ alk\\ phos\\ 78\\ \\ alb\\ 4\\.6\\ \\ tprotein\\ 7\\.9\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ tbili\\ 1\\.1\\ \\ dbili\\ 0\\ \\ iron\\ 98\\ \\ tibc\\ 393\\ \\ fe\\ sat\\ 24\\.9\\%\ \(0\)\
\-\ unknown\\ at\\ this\\ time\\â\\€\\¦resection\\ vs\\.\\ transplantation\\.\\ \\ other\\ options\\ include\\ chemotherapy\\ and\\ radioablation\\.\ \(0\)\
\-\ 2\\.9\\ cm\\ mass\\ in\\ r\\ lobe\\ of\\ liver\\,\\ l\\ liver\\ lobe\\ atrophy\ \(0\)\
\-\ hcc\ \(0\)\
\-\ hepatocellular\\ carcinoma\ \(28\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ focal\\ nodular\\ hyperplasia\ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ metastatic\\ disease\ \(0\)\
\-\ 65\\ yo\\ male\\ with\\ h\\/o\\ hemochromatosis\ \(1\)\
\-\ hcc\\ occurs\\ in\\ 19\\-24\\%\\ of\\ pts\\ with\\ hemochromatosis\\,\\ which\\ is\\ a\\ 20\\ to\\ 200\\ fold\\ increased\\ risk\\ compared\\ with\\ the\\ general\\ population\\ \\(similar\\ to\\ that\\ of\\ pts\\ with\\ cirrhosis\\ secondary\\ to\\ viral\\ hepatitis\\)\\.\\ \\ risk\\ factors\\ include\\ advancing\\ age\\ \\(\\>50\\)\\,\\ male\\ sex\\,\\ and\\ the\\ presence\\ of\\ cirrhosis\\.\\ \\ lft\\â\\€\\™s\\ are\\ often\\ normal\\ as\\ the\\ pathophysiology\\ is\\ not\\ an\\ inflammatory\\ process\\.\\ \\ hcc\\ is\\ the\\ leading\\ cause\\ of\\ death\\ in\\ pts\\ with\\ hemochromatosis\\ \\(approximately\\ 30\\%\\)\\.\\ \\ other\\ causes\\ include\\ cardiac\\ failure\\ resulting\\ from\\ iron\\ deposition\\ in\\ the\\ heart\\ tissue\\ and\\ hepatic\\ failure\\.\\ \ \(0\)\
\-\ fnh\\ is\\ almost\\ always\\ seen\\ in\\ women\\ of\\ childbearing\\ age\\ \\(90\\%\\)\\ and\\ is\\ frequently\\ associated\\ with\\ oral\\ contraceptive\\ use\\.\ \(0\)\
\-\ the\\ remainder\\ of\\ the\\ abdominal\\ pelvic\\ ct\\ was\\ neg\\ for\\ malignancy\\ and\\ pts\\ unremarkable\\ physical\\ exam\\ \\(non\\-cachectic\\)\\ makes\\ mets\\ unlikely\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ pts\\:\\ 0\\.10304602897513625\ \(0\)\
\-\ hemochromatosis\\:\\ 0\\.07728452173135218\ \(0\)\
\-\ hcc\\:\\ 0\\.07353214687328546\ \(0\)\
\-\ iron\\:\\ 0\\.04679592364766393\ \(0\)\
\-\ 1\\.1\\:\\ 0\\.04625226836956537\ \(0\)\
\-\ cirrhosis\\:\\ 0\\.043750685130854235\ \(0\)\
\-\ 34\\.5\\:\\ 0\\.03832834097376738\ \(0\)\
\-\ 6\\.6\\/15\\.2\\/44\\/180\\:\\ 0\\.03832834097376738\ \(0\)\
\-\ a\\-1\\-fetoprotein\\:\\ 0\\.03832834097376738\ \(0\)\
\-\ 37\\/33\\:\\ 0\\.03832834097376738\ \(0\)\
\-\ 393\\:\\ 0\\.03832834097376738\ \(0\)\
\-\ 24\\.9\\:\\ 0\\.03832834097376738\ \(0\)\
\-\ time\\â\\€\\¦resection\\:\\ 0\\.03832834097376738\ \(0\)\
\-\ non\\-cachectic\\:\\ 0\\.03832834097376738\ \(0\)\
\-\ tprotein\\:\\ 0\\.03531465758002849\ \(0\)\
\-\ 19\\-24\\:\\ 0\\.03531465758002849\ \(0\)\
\-\ \\%\\:\\ 0\\.03466645275384361\ \(0\)\
\-\ 14\\.1\\:\\ 0\\.033551765805645166\ \(0\)\
\-\ radioablation\\:\\ 0\\.033551765805645166\ \(0\)\
\-\ \\â\\€\\“\\:\\ 0\\.03344091412513476\ \(0\)\
\-\ ast\\/alt\\:\\ 0\\.0323009741862896\ \(0\)\
\-\ fe\\:\\ 0\\.0323009741862896\ \(0\)\
\-\ 7\\.9\\:\\ 0\\.03133078483274956\ \(0\)\
\-\ dbili\\:\\ 0\\.03133078483274956\ \(0\)\
\-\ tibc\\:\\ 0\\.03133078483274956\ \(0\)\
\-\ include\\:\\ 0\\.0312672194090907\ \(0\)\
\-\ advancing\\:\\ 0\\.030538082411906274\ \(0\)\
\-\ contraceptive\\:\\ 0\\.030538082411906274\ \(0\)\
\-\ childbearing\\:\\ 0\\.02986786206483124\ \(0\)\
\-\ failure\\:\\ 0\\.0291083328941858\ \(0\)\
\-\ 4\\.6\\:\\ 0\\.02877519063752295\ \(0\)\
\-\ alb\\:\\ 0\\.027524399018167382\ \(0\)\
\-\ lft\\:\\ 0\\.027524399018167382\ \(0\)\
\-\ fnh\\:\\ 0\\.027524399018167382\ \(0\)\
\-\ risk\\:\\ 0\\.026914840411818144\ \(0\)\
\-\ 2\\.9\\:\\ 0\\.026554209664627338\ \(0\)\
\-\ ptt\\:\\ 0\\.02627360739881181\ \(0\)\
\-\ sex\\:\\ 0\\.026010022086566446\ \(0\)\
\-\ liver\\:\\ 0\\.025619317485501947\ \(0\)\
\-\ 200\\:\\ 0\\.025526432368695905\ \(0\)\
\-\ tbili\\:\\ 0\\.02509128689670902\ \(0\)\
\-\ pathophysiology\\:\\ 0\\.02488902595916601\ \(0\)\
\-\ transplantation\\:\\ 0\\.024695757426249344\ \(0\)\
\-\ fold\\:\\ 0\\.024695757426249344\ \(0\)\
\-\ 1\\.9\\:\\ 0\\.02433322869173173\ \(0\)\
\-\ inr\\:\\ 0\\.02325992400507292\ \(0\)\
\-\ 98\\:\\ 0\\.02299633869282755\ \(0\)\
\-\ neg\\:\\ 0\\.022747823850045167\ \(0\)\
\-\ age\\:\\ 0\\.02261661152647223\ \(0\)\
\-\ 78\\:\\ 0\\.022512748974957014\ \(0\)\
\-\ 0\\:\\ 0\\.02228973465153288\ \(0\)\
\-\ alk\\:\\ 0\\.02168207403251045\ \(0\)\
\-\ phos\\:\\ 0\\.02168207403251045\ \(0\)\
\-\ hepatocellular\\:\\ 0\\.021407383155895094\ \(0\)\
\-\ mets\\:\\ 0\\.021407383155895094\ \(0\)\
\-\ hepatitis\\:\\ 0\\.021319545297992834\ \(0\)\
\-\ sat\\:\\ 0\\.021149020458195958\ \(0\)\
\-\ deposition\\:\\ 0\\.020749857200573686\ \(0\)\
\-\ makes\\:\\ 0\\.02059991730461208\ \(0\)\
\-\ death\\:\\ 0\\.020047068715545794\ \(0\)\
\-\ lobe\\:\\ 0\\.019994133460204642\ \(0\)\
\-\ h\\/o\\:\\ 0\\.019386128683812637\ \(0\)\
\-\ population\\:\\ 0\\.019386128683812637\ \(0\)\
\-\ atrophy\\:\\ 0\\.019168692072618457\ \(0\)\
\-\ always\\:\\ 0\\.01911599050508652\ \(0\)\
\-\ viral\\:\\ 0\\.018715908336737603\ \(0\)\
\-\ hyperplasia\\:\\ 0\\.018305861904253942\ \(0\)\
\-\ 65\\:\\ 0\\.01813533706445707\ \(0\)\
\-\ options\\:\\ 0\\.01805251882545405\ \(0\)\
\-\ women\\:\\ 0\\.01805251882545405\ \(0\)\
\-\ almost\\:\\ 0\\.01797124868192295\ \(0\)\
\-\ noncontributory\\:\\ 0\\.017813128489875665\ \(0\)\
\-\ leading\\:\\ 0\\.01777448089240938\ \(0\)\
\-\ unlikely\\:\\ 0\\.017698201285231512\ \(0\)\
\-\ 90\\:\\ 0\\.017513159483410663\ \(0\)\
\-\ remainder\\:\\ 0\\.017513159483410663\ \(0\)\
\-\ other\\:\\ 0\\.01712729172784738\ \(0\)\
\-\ l\\:\\ 0\\.016937119557123362\ \(0\)\
\-\ r\\:\\ 0\\.016874106481894812\ \(0\)\
\-\ pe\\:\\ 0\\.016690368180634452\ \(0\)\
\-\ factors\\:\\ 0\\.016690368180634452\ \(0\)\
\-\ cbc\\:\\ 0\\.01660133108783645\ \(0\)\
\-\ resulting\\:\\ 0\\.016317058221476225\ \(0\)\
\-\ frequently\\:\\ 0\\.016102307111347632\ \(0\)\
\-\ compared\\:\\ 0\\.015726179968263795\ \(0\)\
\-\ \\(\\:\\ 0\\.01570351578791001\ \(0\)\
\-\ general\\:\\ 0\\.015654707245032665\ \(0\)\
\-\ oral\\:\\ 0\\.015654707245032665\ \(0\)\
\-\ nodular\\:\\ 0\\.015584390465703963\ \(0\)\
\-\ hepatic\\:\\ 0\\.015515192833939184\ \(0\)\
\-\ \\)\\:\\ 0\\.015511688958984892\ \(0\)\
\-\ occurs\\:\\ 0\\.015248916202457797\ \(0\)\
\-\ pelvic\\:\\ 0\\.015248916202457797\ \(0\)\
\-\ use\\:\\ 0\\.01468451789149262\ \(0\)\
\-\ vs\\:\\ 0\\.014628173784351295\ \(0\)\
\-\ similar\\:\\ 0\\.014572550517134297\ \(0\)\
\-\ unknown\\:\\ 0\\.014499476089671769\ \(0\)\
\-\ causes\\:\\ 0\\.014463394338303528\ \(0\)\
\-\ malignancy\\:\\ 0\\.014356911642615287\ \(0\)\
\-\ process\\:\\ 0\\.014304632542759628\ \(0\)\
\-\ 30\\:\\ 0\\.014287344941109021\ \(0\)\
\-\ cardiac\\:\\ 0\\.014151464317178132\ \(0\)\
\-\ 50\\:\\ 0\\.014134773985407847\ \(0\)\
\-\ pt\\:\\ 0\\.013813755454925011\ \(0\)\
\-\ presence\\:\\ 0\\.013486024428074474\ \(0\)\
\-\ male\\:\\ 0\\.01343656989467368\ \(0\)\
\-\ 20\\:\\ 0\\.013358761896334852\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.01331715558756898\ \(0\)\
\-\ labs\\:\\ 0\\.012921626117109297\ \(0\)\
\-\ heart\\:\\ 0\\.012909041951777278\ \(0\)\
\-\ inflammatory\\:\\ 0\\.012883982366052277\ \(0\)\
\-\ cause\\:\\ 0\\.01257070707196507\ \(0\)\
\-\ \\>\\:\\ 0\\.012344206585515497\ \(0\)\
\-\ unremarkable\\:\\ 0\\.012300288776878525\ \(0\)\
\-\ is\\:\\ 0\\.012223712573580991\ \(0\)\
\-\ often\\:\\ 0\\.011854232819650663\ \(0\)\
\-\ approximately\\:\\ 0\\.011494860115459056\ \(0\)\
\-\ yo\\:\\ 0\\.01117978923175114\ \(0\)\
\-\ \\â\\€\\™\\:\\ 0\\.011104464085415025\ \(0\)\
\-\ s\\:\\ 0\\.010655511596150379\ \(0\)\
\-\ focal\\:\\ 0\\.010610841757123486\ \(0\)\
\-\ carcinoma\\:\\ 0\\.010530120304416812\ \(0\)\
\-\ secondary\\:\\ 0\\.010387086810907858\ \(0\)\
\-\ cm\\:\\ 0\\.009965026599204287\ \(0\)\
\-\ metastatic\\:\\ 0\\.009352649580939523\ \(0\)\
\-\ abdominal\\:\\ 0\\.009286605383139631\ \(0\)\
\-\ in\\:\\ 0\\.009160809350875107\ \(0\)\
\-\ physical\\:\\ 0\\.009115240302527123\ \(0\)\
\-\ increased\\:\\ 0\\.009089064268694155\ \(0\)\
\-\ tissue\\:\\ 0\\.008806179080228668\ \(0\)\
\-\ associated\\:\\ 0\\.008767228530033486\ \(0\)\
\-\ exam\\:\\ 0\\.008161886695432774\ \(0\)\
\-\ seen\\:\\ 0\\.00734185919594648\ \(0\)\
\-\ which\\:\\ 0\\.006935411248880647\ \(0\)\
\-\ that\\:\\ 0\\.006417307515473145\ \(0\)\
\-\ disease\\:\\ 0\\.006072771918329148\ \(0\)\
\-\ normal\\:\\ 0\\.005824401976517831\ \(0\)\
\-\ as\\:\\ 0\\.005619902199539686\ \(0\)\
\-\ to\\:\\ 0\\.005570453588386777\ \(0\)\
\-\ from\\:\\ 0\\.005506242231105271\ \(0\)\
\-\ not\\:\\ 0\\.005368776833660589\ \(0\)\
\-\ ct\\:\\ 0\\.00519697240605236\ \(0\)\
\-\ mass\\:\\ 0\\.005167221769337237\ \(0\)\
\-\ an\\:\\ 0\\.005137673322977087\ \(0\)\
\-\ are\\:\\ 0\\.005064669010998268\ \(0\)\
\-\ at\\:\\ 0\\.005033752838398404\ \(0\)\
\-\ \\,\\:\\ 0\\.004708001139431085\ \(0\)\
\-\ was\\:\\ 0\\.004296858792233421\ \(0\)\
\-\ the\\:\\ 0\\.004207586925762524\ \(0\)\
\-\ this\\:\\ 0\\.004178857449191883\ \(0\)\
\-\ and\\:\\ 0\\.003913239255048227\ \(0\)\
\-\ of\\:\\ 0\\.003545767850373561\ \(0\)\
\-\ for\\:\\ 0\\.00317003542888137\ \(0\)\
\-\ with\\:\\ 0\\.0030522828545188627\ \(0\)\
\-\ a\\:\\ 0\\.0017243469644287013\ \(0\)\
\-\ \\.\\:\\ 0\\.0015434580911889684\ \(0\)\
